FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310127242> ?p ?o ?g. }

• W4310127242 endingPage "6831" @default.
• W4310127242 startingPage "6830" @default.
• W4310127242 abstract "Background SARS-CoV-2 infection has been associated with a poor prognosis in patients with Philadelphia-negative myeloproliferative neoplasms (MPN).(Passamonti et al. Lancet Haematol. 2020;7(10):e737-e745). Nevertheless, given the concerns about SARS-CoV-2 vaccine-associated thrombosis (Pavord et al. N Engl J Med 2021;385(18):1680-1689) and the well-known thrombotic risk associated with MPN (De Stefano et al. Leukemia 2016;30(10):2032-2038), patients had frequently vaccine-hesitancy and some of them even refused to be vaccinated. Methods To estimate the potential risk of thrombosis associated with SARS-CoV-2 vaccination in MPN, we evaluated 335 consecutive MPN patients vaccinated against SARS-CoV-2 with at least one dose. Proportional hazard Cox model for multiple failures was used to compare the risk of thrombotic complications according to vaccine exposure (treated as time-dependent covariate), and results of these models were reported in terms of Hazard Ratio (HR) for vaccine exposure vs non-exposure periods, together with its 95% Confidence Interval (95%CI). The exposure period was defined for each patient from the date of any SARS-CoV-2 vaccine dose till 30 days after; the non-exposure period included for each patient the six months before the first dose and the period beyond 30 days after each dose till last follow-up (see Figure 1A). To take into account time between diagnosis and enter date, left-truncation was applied. Results Starting from January 2021 we enrolled 335 MPN patients, including 99 affected with PV, 176 affected with ET, 49 affected with primary or secondary myelofibrosis and 11 affected with MPN unclassifiable. Median age was 55 years (range 15-88); 153 (46%) were males and 182 (54%) were females. Considering the mutational status, 252 patients (75.2%) were JAK2 V617F-mutated, 55 patients (16.4%) were CALR-mutated, 6 patients (1.8%) were MPL-mutated and 22 patients (6.6%) were triple negative. Seventy out of 335 patients (20.9%) were not receiving cytoreduction at the time of vaccination; the remaining 265 (79.1%) were under cytoreductive treatment (226 with hydroxyurea, 22 with ruxolitinib, 13 with interferon, 4 with busulfan). A previous history of thrombosis was reported in 100/335 (0.3%). Almost all patients received at least two doses of vaccination against SARS-CoV-2 (331/335, 98.8%); 75% of patients (224 of 335) received also the third dose. In most patients (320/335, 95.5%) the first two doses consisted of mRNA-based vaccines; in only 15 out of 335 (4.5%) the first two doses consisted of adenovirus-vectored vaccines. In all cases the third vaccination was performed with mRNA-based vaccines. Thrombotic complications included only major thrombosis. The risk of thrombosis in the exposure period did not significantly differ from the risk of thrombosis in the non-exposure period (HR=0.8; 95%CI 0.04-15.4, P 0.866), as shown in Figure 1B. No case of cerebral venous thrombosis was reported in the post-vaccine period. Conclusions Although these results need to be confirmed in larger studies, these data deliver an important message to the clinical community: SARS-CoV-2 vaccines do not increase the risk of thrombosis in MPN patients; thus, it is pivotal for health care professional to vaccinate the highest number of MPN patients, reassuring them regarding thrombotic complications. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310127242 created "2022-11-30" @default.
• W4310127242 creator A5009436567 @default.
• W4310127242 creator A5017183604 @default.
• W4310127242 creator A5018389999 @default.
• W4310127242 creator A5018792236 @default.
• W4310127242 creator A5019034145 @default.
• W4310127242 creator A5019208096 @default.
• W4310127242 creator A5025846371 @default.
• W4310127242 creator A5031234325 @default.
• W4310127242 creator A5059059593 @default.
• W4310127242 creator A5082541910 @default.
• W4310127242 date "2022-11-15" @default.
• W4310127242 modified "2023-09-28" @default.
• W4310127242 title "Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination" @default.
• W4310127242 doi "https://doi.org/10.1182/blood-2022-157967" @default.
• W4310127242 hasPublicationYear "2022" @default.
• W4310127242 type Work @default.
• W4310127242 citedByCount "0" @default.
• W4310127242 crossrefType "journal-article" @default.
• W4310127242 hasAuthorship W4310127242A5009436567 @default.
• W4310127242 hasAuthorship W4310127242A5017183604 @default.
• W4310127242 hasAuthorship W4310127242A5018389999 @default.
• W4310127242 hasAuthorship W4310127242A5018792236 @default.
• W4310127242 hasAuthorship W4310127242A5019034145 @default.
• W4310127242 hasAuthorship W4310127242A5019208096 @default.
• W4310127242 hasAuthorship W4310127242A5025846371 @default.
• W4310127242 hasAuthorship W4310127242A5031234325 @default.
• W4310127242 hasAuthorship W4310127242A5059059593 @default.
• W4310127242 hasAuthorship W4310127242A5082541910 @default.
• W4310127242 hasBestOaLocation W43101272422 @default.
• W4310127242 hasConcept C116675565 @default.
• W4310127242 hasConcept C126322002 @default.
• W4310127242 hasConcept C159047783 @default.
• W4310127242 hasConcept C203014093 @default.
• W4310127242 hasConcept C22070199 @default.
• W4310127242 hasConcept C2779134260 @default.
• W4310127242 hasConcept C2780868729 @default.
• W4310127242 hasConcept C3006700255 @default.
• W4310127242 hasConcept C3007834351 @default.
• W4310127242 hasConcept C3008058167 @default.
• W4310127242 hasConcept C524204448 @default.
• W4310127242 hasConcept C71924100 @default.
• W4310127242 hasConcept C89623803 @default.
• W4310127242 hasConceptScore W4310127242C116675565 @default.
• W4310127242 hasConceptScore W4310127242C126322002 @default.
• W4310127242 hasConceptScore W4310127242C159047783 @default.
• W4310127242 hasConceptScore W4310127242C203014093 @default.
• W4310127242 hasConceptScore W4310127242C22070199 @default.
• W4310127242 hasConceptScore W4310127242C2779134260 @default.
• W4310127242 hasConceptScore W4310127242C2780868729 @default.
• W4310127242 hasConceptScore W4310127242C3006700255 @default.
• W4310127242 hasConceptScore W4310127242C3007834351 @default.
• W4310127242 hasConceptScore W4310127242C3008058167 @default.
• W4310127242 hasConceptScore W4310127242C524204448 @default.
• W4310127242 hasConceptScore W4310127242C71924100 @default.
• W4310127242 hasConceptScore W4310127242C89623803 @default.
• W4310127242 hasIssue "Supplement 1" @default.
• W4310127242 hasLocation W43101272421 @default.
• W4310127242 hasLocation W43101272422 @default.
• W4310127242 hasOpenAccess W4310127242 @default.
• W4310127242 hasPrimaryLocation W43101272421 @default.
• W4310127242 hasRelatedWork W3025176011 @default.
• W4310127242 hasRelatedWork W3032320397 @default.
• W4310127242 hasRelatedWork W3033635008 @default.
• W4310127242 hasRelatedWork W3152606407 @default.
• W4310127242 hasRelatedWork W3160610681 @default.
• W4310127242 hasRelatedWork W4210401150 @default.
• W4310127242 hasRelatedWork W4280491013 @default.
• W4310127242 hasRelatedWork W4308017287 @default.
• W4310127242 hasRelatedWork W4367397324 @default.
• W4310127242 hasRelatedWork W3107152225 @default.
• W4310127242 hasVolume "140" @default.
• W4310127242 isParatext "false" @default.
• W4310127242 isRetracted "false" @default.
• W4310127242 workType "article" @default.